ArticleCureus2025
Zinc as an Adjuvant Therapy in Acute Severe Pneumonia in Children Aged Two Months to Two Years: A Double-Blind Randomized Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe study aimed to evaluate the efficacy of zinc supplementation, in addition to standard antimicrobial therapy, in the treatment of severe pneumonia among hospitalized rural Indian children aged 2-24 months. It also sought to identify factors associated with the development of pneumonia in this population. METHODOLOGY: A hospital-based, randomized, double-blinded, placebo-controlled trial was conducted from September to December 2022, registered with the Clinical Trial Registry of India (CTRI/2022/09/046070). A total of 94 children with severe pneumonia were randomly assigned to receive either 10 mg of zinc gluconate (2.5 ml) or a placebo twice daily during hospitalization, along with standard therapy. Clinical signs, symptoms, and laboratory parameters were monitored, and baseline characteristics were compared between the groups.
resultsThe median duration of cough and cold in the Zinc group was significantly shorter compared to the Control group (p = 0.013, p = 0.005, respectively). Among stunted children, those in the Zinc group required about 3.12 fewer days for recovery compared to those in the Control group, and this difference was statistically significant (p = 0.05). However, no statistically significant differences were observed between the groups in the duration of tachypnea, hypoxia, chest indrawing, inability to feed, lethargy, severe illness, or overall hospitalization.
conclusionWhile zinc supplementation demonstrated potential benefits such as reduced hospital stay and faster symptom resolution, these differences were not statistically significant. Further research is needed to validate zinc role in improving clinical outcomes in severe pediatric pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.